Biotinyl tyramide blocking orally active dual Src/Bcr-Abl inhibitor

orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity

leading to subsequent fusion with the plasma membrane

and/or apoptosis research

Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2

Golgi apparatus

Biotinyl tyramide blocking orally active dual Src/Bcr-Abl inhibitorBiotin derivative. Substrate of the horseradish peroxidase enzyme and used as a reagent to amplify immunohistochemical signals. It is based on the HRP catalyzed deposition of tyramide conjugates (such as biotinyl tyramide) on a solid phase. Subsequent reaction with streptavidin fluorophore results in the localization of the fluorophore at the site of tyramide deposition. This fluorescence based tyramide signal amplification (TSA) has been widely used